Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) announced today that its tax benefit preservation plan had expired pursuant to its terms, effectively terminating the plan as of August 1, 2017. Stockholders are not required to take any action as a result of this expiration.
In connection with the expiration of the tax benefit preservation plan, Fluidigm will be taking routine actions to voluntarily deregister the related preferred share purchase rights under the Securities Exchange Act of 1934, and to delist the preferred share purchase rights from NASDAQ. These actions are administrative in nature and will have no effect on Fluidigm’s common stock, which continues to be listed on NASDAQ.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650.243.6628 (Office) [email protected]
